Research programme: stem cell therapeutics - Trillium Therapeutics
Latest Information Update: 16 Jun 2014
At a glance
- Originator Stem Cell Therapeutics Corp.
- Developer Trillium Therapeutics Inc
- Mechanism of Action Cell stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- No development reported Cardiovascular disorders